{
  "item1": "Alliance revenue represents Merckâ€™s share profits, which product sales net cost sales commercialization costs. Other revenues primarily comprised miscellaneous corporate revenues, including revenue hedging activities, well revenue third-party manufacturing arrangements. Pharmaceutical segment includes human health pharmaceutical vaccine products. Human health pharmaceutical products consist therapeutic preventive agents, generally sold prescription, treatment human disorders.",
  "item7": "OCI) , depending whether derivative designated part hedge transaction and, if so, type hedge transaction. derivatives designated cash flow hedges, unrealized gains losses these contracts recorded Accumulated Other Comprehensive Loss AOCL) reclassified into when hedged anticipated revenue recognized. amount reclassified into earnings result discontinuation cash flow hedges because no longer deemed probable forecasted hedged transactions would occur not material years ended December 31, 2024, 2023 2022. those derivatives which not designated cash flow hedges, but serve economic hedges forecasted sales, unrealized gains losses recorded each period.",
  "item2": "(pembrolizumab berahyaluronidase alfa-pmph) injection subcutaneous administration across most solid tumor indications , subsequently approved treatment certain adult patients resectable locally advanced HNSCC so now approved across all solid tumor indications Lynparza oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed commercialized part collaboration AstraZeneca PLC (AstraZeneca) (see Note 3 condensed consolidated financial statements). Lynparza approved treatment certain types advanced recurrent ovarian, early metastatic breast, metastatic pancreatic metastatic castration-resistant prostate cancers. Alliance revenue related Lynparza increased 12% both third quarter first nine months 2025, primarily due higher demand U.S. certain international markets."
}